357 related articles for article (PubMed ID: 30875057)
21. Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.
Calabrò D; Argalia G; Ambrosini V
Diagnostics (Basel); 2020 Dec; 10(12):. PubMed ID: 33297381
[TBL] [Abstract][Full Text] [Related]
22. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
23. 68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI.
Janssen I; Chen CC; Taieb D; Patronas NJ; Millo CM; Adams KT; Nambuba J; Herscovitch P; Sadowski SM; Fojo AT; Buchmann I; Kebebew E; Pacak K
J Nucl Med; 2016 Feb; 57(2):186-91. PubMed ID: 26564322
[TBL] [Abstract][Full Text] [Related]
24.
Leupe H; Ahenkorah S; Dekervel J; Unterrainer M; Van Cutsem E; Verslype C; Cleeren F; Deroose CM
J Nucl Med; 2023 Jun; 64(6):835-841. PubMed ID: 37169533
[TBL] [Abstract][Full Text] [Related]
25. Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors.
Panagiotidis E; Bomanji J
PET Clin; 2014 Jan; 9(1):43-55. PubMed ID: 25029933
[TBL] [Abstract][Full Text] [Related]
26. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
27. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases.
Archier A; Varoquaux A; Garrigue P; Montava M; Guerin C; Gabriel S; Beschmout E; Morange I; Fakhry N; Castinetti F; Sebag F; Barlier A; Loundou A; Guillet B; Pacak K; Taïeb D
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1248-57. PubMed ID: 26637204
[TBL] [Abstract][Full Text] [Related]
28. Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?
Santhanam P; Chandramahanti S; Kroiss A; Yu R; Ruszniewski P; Kumar R; Taïeb D
Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1144-55. PubMed ID: 25771906
[TBL] [Abstract][Full Text] [Related]
29. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.
Kauhanen S; Seppänen M; Ovaska J; Minn H; Bergman J; Korsoff P; Salmela P; Saltevo J; Sane T; Välimäki M; Nuutila P
Endocr Relat Cancer; 2009 Mar; 16(1):255-65. PubMed ID: 19088184
[TBL] [Abstract][Full Text] [Related]
30. Nuclear medicine in NET.
Sorschag M; Malle P; Gallowitsch HJ
Wien Med Wochenschr; 2012 Oct; 162(19-20):416-22. PubMed ID: 22810487
[TBL] [Abstract][Full Text] [Related]
31. Functional imaging of neuroendocrine tumors.
Van Binnebeek S; Karges W; Mottaghy FM
Methods Mol Biol; 2011; 727():105-22. PubMed ID: 21331931
[TBL] [Abstract][Full Text] [Related]
32. 18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors.
Minn H; Kemppainen J; Kauhanen S; Forsback S; Seppänen M
PET Clin; 2014 Jan; 9(1):27-36. PubMed ID: 25029931
[TBL] [Abstract][Full Text] [Related]
33. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
34. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.
Kjaer A; Knigge U
Scand J Gastroenterol; 2015 Jun; 50(6):740-7. PubMed ID: 25959100
[TBL] [Abstract][Full Text] [Related]
35. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.
Ambrosini V; Kunikowska J; Baudin E; Bodei L; Bouvier C; Capdevila J; Cremonesi M; de Herder WW; Dromain C; Falconi M; Fani M; Fanti S; Hicks RJ; Kabasakal L; Kaltsas G; Lewington V; Minozzi S; Cinquini M; Öberg K; Oyen WJG; O'Toole D; Pavel M; Ruszniewski P; Scarpa A; Strosberg J; Sundin A; Taïeb D; Virgolini I; Wild D; Herrmann K; Yao J
Eur J Cancer; 2021 Mar; 146():56-73. PubMed ID: 33588146
[TBL] [Abstract][Full Text] [Related]
36. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
37. The radionuclide molecular imaging and therapy of neuroendocrine tumors.
Li S; Beheshti M
Curr Cancer Drug Targets; 2005 Mar; 5(2):139-48. PubMed ID: 15810878
[TBL] [Abstract][Full Text] [Related]
38. [Assessment of a neuroendocrine tumour by 111In-pentetreotid scintigraphy and PET with 18FFDOPA and 18F-FDG].
Plaza P; Montravers F; Aide N; Carrera D; Kerrou K; Ferran N; Grahek D; Talbot JN
Rev Esp Med Nucl; 2004; 23(6):421-4. PubMed ID: 15625060
[TBL] [Abstract][Full Text] [Related]
39. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
[TBL] [Abstract][Full Text] [Related]
40. Comparison of different positron emission tomography tracers in patients with recurrent medullary thyroid carcinoma: our experience and a review of the literature.
Treglia G; Castaldi P; Villani MF; Perotti G; Filice A; Ambrosini V; Cremonini N; Versari A; Fanti S; Giordano A; Rufini V
Recent Results Cancer Res; 2013; 194():385-93. PubMed ID: 22918771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
